Moderna
MRNA
673 hedge funds and large institutions have $8.99B invested in Moderna in 2025 Q4 according to their latest regulatory filings, with 112 funds opening new positions, 168 increasing their positions, 254 reducing their positions, and 70 closing their positions.
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
60% more first-time investments, than exits
New positions opened: 112 | Existing positions closed: 70
26% more capital invested
Capital invested by funds: $7.12B → $8.99B (+$1.88B)
7.14% more ownership
Funds ownership: 70.71% → 77.86% (+7.1%)
5% more funds holding
Funds holding: 644 → 673 (+29)
5% less call options, than puts
Call options by funds: $1.41B | Put options by funds: $1.49B
34% less repeat investments, than reductions
Existing positions increased: 168 | Existing positions reduced: 254
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$428M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$349M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$87.7M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$83.1M |
| 5 |
BlackRock
New York
|
+$80.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$38.3M |
| 2 |
Jane Street
New York
|
-$36.9M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$34.4M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$33.5M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$32.2M |
MRNA Hedge Fund Activity: Q4 2025 in Review
673 institutional investors reported a position in Moderna (MRNA) for Q4 2025, worth a combined $8.99B — up 26% from $7.12B a quarter earlier.
Buyers outnumbered sellers: 112 funds opened new MRNA positions and 70 closed out — a net gain of 42 holders — while 168 added to existing stakes and 254 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $428M. The largest seller was Citadel Advisors, cutting an estimated $38.3M.
- 673 institutional investors held Moderna (MRNA) as of Q4 2025, up from 644 in Q3 2025.
- Funds reported $8.99B of Moderna stock for Q4 2025, up 26% quarter-over-quarter.
- 112 funds opened new Moderna positions in Q4 2025 and 70 closed out, a net change of +42 holders.
- The largest Moderna buyer in Q4 2025 was Fidelity Investments, an estimated $428M added.
- The largest Moderna seller in Q4 2025 was Citadel Advisors, an estimated $38.3M sold.
Based on aggregated 13F filings for Q4 2025.